Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $500 million aggregate principal amount of 1 ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt ...